

Check for updates

Requirements for confirmation of PCR-RFLP results of polymorphisms

Dear Editor

As clinical investigators and researchers exploring the role of insulin receptor gene (INSR) in polycystic ovary syndrome (PCOS), we wish to express our concern about the study by Tehrani *et al.* (1) that aimed to explore the correlation between INSR and adiponectin genes and PCOS. We are afraid that it might have technical flaws and take confusion and concerns to the readership.

First, in the Materials and Methods section the authors stated that this study was a cross-sectional study, while in the Conclusion section they called it a case-control study. It is really confusing. This reveals a lack of statistical understanding of the cross-sectional or case-control studies and reduces the power of the study.

Most critically, we are concerned about the performance of the polymerase chain reaction-restriction fragments length polymorphism analysis (PCR-RFLP). Quality control is a major issue in the application of PCR-RFLP studies, and for this reason we usually adopt some quality control procedures, including using positive and negative controls, repeating the genotyping analysis, and confirming the results with DNA sequencing (2, 3). However, in this study no quality control program was represented in the genotyping section.

A series of studies have investigated the different genotypes of INSR in PCOS and control populations. Nearly all the reports showed that the least frequent genotype of rs1799817 was TT in both control and PCOS groups (2, 4–13), while in this study the most frequent one was TT. Meanwhile, for rs2059806, all the other reports showed that the least frequent genotype was AA (2, 8, 12), while this study found that the most frequent one was AA. Additionally, a study from Iran was included in these studies, which showed that the genotype frequencies of CC/CT/TT of rs1799817 were 110/63/8 in control group and 105/64/12 in PCOS group (2), and the genotypes of GG/GA/AA of rs2059806 were 93/70/18 in control group and 96/73/12 in PCOS group (2). In this study, the genotypes of CC/CT/TT of rs1799817 were 7/54/95 in control population and 15/57/114 in PCOS population, and the genotypes of GG/GA/AA of rs2059806 were 18/58/80 in control and 11/76/99 in PCOS population. This distribution of genotypes is completely contradictory to the previously published one (2). Considering that they were carried out in the same ethnicity, it is difficult to explain it. This disaccordance raised a question about the molecular methods applied to define the genotypes. Further confirmation was required to make their results persuasive.

The authors also listed the allele frequencies in Table III. When we calculated the allele frequencies using the genotype frequencies provided by them, we obtained totally

Corresponding Author:

Chun Feng;

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310006, China.

email: doctovfc@zju.edu.cn

Production and Hosting by Knowledge E

© Chun Feng *et al.* This article is distributed under the terms of the Creative

Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Editor-in-Chief: Aflatoonian Abbas M.D.

Letter to Editor

different results. For rs2059806 in PCOS, the frequency of allele A (FA) was calculated as FAA*2 +FAG*1 = 99*2+76*1 = 274, and FG was calculated as FGG*2+FAG*1 = 11*2+76*1 = 98. However, the reported allele frequency of A was 110 and that of G was 76. Could the authors explain how they calculated the allele frequencies?

Finally, in Table IV, the haplotype of Insulin in PCOS included CA, CG, TA, and CG, which shows that a TG was likely mistaken as a CG, and therefore CG duplicated here. Similarly, the same problem happened in the haplotype of Insulin in controls too. In Figure 1, a TG might have been replaced by a CG too. What's more, the data labels of the haplotypes are not accurate either. There are three numbers without decimal places, including 7, 28, and 25, which should be 7.0, 28.0, and 25.8.

Chun Feng¹ M.D., Ping-ping Lv^2 Ph.D. Candidate, Min Jin³ M.D., Ph.D., Jin-Ming Shen⁴ M.D., Tian-he Huang⁵ M.D.

¹Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ³¹⁰⁰⁰⁶, China. ²Key Laboratory of Reproductive Genetics, Ministry of Education (Zhejiang University), ^{Hangzhou,} Zhejiang, 310058, China.

³The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ^{Zhejiang,} 310009, China.

⁴The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, ^{Zhejiang, 310018,} China.

⁵The First Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, ^{Shanxi, 710061,} China.

References

- [1] Ramezani Tehrani F, Daneshpour M, Hashemi S, Zarkesh M, Azizi F. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. *Iran J Reprod Med* 2013; 11: 185–194.
- [2] Ranjzad F, Mahmoudi T, Irani Shemirani A, Mahban A, Nikzamir A, Vahedi M, *et al*. A common variant in the adiponectin gene and polycystic ovary syndrome risk. *Mol Biol Rep* 2012; 39: 2313–2319.
- [3] Murillo R, Munoz D, Williams T, Mugeta N, Caballero P. Application of the PCR-RFLP method for the rapid differentiation of Spodoptera exigua nucleopolyhedrovirus genotypes. *J Virol Methods* 2006; 135: 1–8.
- [4] Chen ZJ, Shi YH, Zhao YR, Li Y, Tang R, Zhao LX, *et al.* [Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome]. *Zhonghua Fu Chan Ke Za Zhi* 2004; 39: 582–585.
- [5] Conway GS, Avey C, Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. *Hum Reprod* 1994; 9: 1681–1683.
- [6] Lee EJ, Yoo KJ, Kim SJ, Lee SH, Cha KY, Baek KH. Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. *Fertil Steril* 2006; 86: 380–384.
- [7] Kashima K, Yahata T, Fujita K, Tanaka K. Polycystic ovary syndrome: association of a C/T single nucleotide polymorphism at tyrosine kinase domain of insulin receptor gene with pathogenesis among lean Japanese women. J Reprod Med 2013; 58: 491–496.
- [8] Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O'Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996; 81: 1979–1983.

- [9] Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N, et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160: 855–862.
- [10] Skrgatic L, Baldani DP, Gersak K, Cerne JZ, Ferk P, Coric M. Genetic polymorphisms of INS, INSR and IRS-1 genes are not associated with polycystic ovary syndrome in Croatian women. *Coll Antropol* 2013; 37: 141–146.
- [11] Ramos Cirilo PD, Rosa FE, Moreira Ferraz MF, Rainho CA, Pontes A, Rogatto SR. Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome. *Gynecol Endocrinol* 2012; 28: 190–194.
- [12] Lee EJ, Oh B, Lee JY, Kimm K, Lee SH, Baek KH. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. *Fertil Steril* 2008; 89: 1213–1220.
- [13] Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. *Fertil* Steril 2002; 78: 1240–1243.

Authors' Answer

We thank Chun Feng and Colleagues for their interest in our paper (1). The issues raised (letter) concerning our study are important; this reply letter clarifies our methodology and corrects some results in detail.

A case-control study is a type of observational study in which two existing groups differing in outcomes are identified and compared on the basis of some supposed causal attribute, whereas a cross-sectional study provides a "snapshot" of a population at a single point in time and looks at both the diseases along with assumed covariates simultaneously (2). Our study was a case-control study in which a total of 186 women with PCOS using NIH criteria (cases) and 156 healthy women (controls) were recruited. At that time, we used the polymerase chain reaction-restriction fragments length polymorphism analysis (PCR-RFLP), and due to limited financial resources, we did not perform DNA sequencing; however, we used positive and negative control groups in each PCR. There was a typo error in the presentation of genotypes of INSR in our manuscript that created all the discrepancies between our results and those previously reported (3). We believe that the revised results presented in Table III will resolve the discrepancies. Results presented in this table should be replaced with the previous results presented in Table III of the original article and the corresponding texts in the Results section.

Genotype frequency (%)AdiponectinSmal T > G (rs2241766)GG2 (1.1)GG2 (1.1)TT142 (76.3)TG42 (22.6)46 (29.5)Bsmal C > A (rs1501299)CC92 (49.5)77 (49.4)AA18 (9.7)AA18 (9.7)StatisticInsulinPm1l T > C (rs1799817)TT114 (61.3)QC15 (8.1)7 (4.5)		PCOS (n = 186)	Controls (n = 156)
Smal T > G (rs2241766) GG 2 (1.1) 4 (2.6) TT 142 (76.3) 106 (67.9) TG 42 (22.6) 46 (29.5) Bsmal C > A (rs1501299) 77 (49.4) CC 92 (49.5) 77 (49.4) AA 18 (9.7) 8 (5.1) CA 76 (40.9) 71 (45.5) Insulin 71 114 (61.3) 95 (60.9)	Genotype frequency (%)		
GG2 (1.1)4 (2.6)TT142 (76.3)106 (67.9)TG42 (22.6)46 (29.5)Bsmal C > A (rs1501299) 77 (49.4)CC92 (49.5)77 (49.4)AA18 (9.7)8 (5.1)CA76 (40.9)71 (45.5)Insulin 71 (45.5)Pm1l T > C (rs1799817) 114 (61.3)95 (60.9)	Adiponectin		
TT142 (76.3)106 (67.9)TG42 (22.6)46 (29.5)Bsmal C > A (rs1501299) CC 92 (49.5)77 (49.4)AA18 (9.7)8 (5.1)CA76 (40.9)71 (45.5)Insulin $Pm11 T > C (rs1799817)$ TT 114 (61.3)95 (60.9)	Smal T > G (rs2241766)		
TG42 (22.6)46 (29.5)Bsmal C > A (rs1501299)CC92 (49.5)77 (49.4)AA18 (9.7)8 (5.1)CA76 (40.9)71 (45.5)Insulin $Pm11 T > C (rs1799817)$ TT TT114 (61.3)95 (60.9)	GG	2 (1.1)	4 (2.6)
Bsmal C > A (rs1501299) CC 92 (49.5) 77 (49.4) AA 18 (9.7) 8 (5.1) CA 76 (40.9) 71 (45.5) Insulin Pm1I T > C (rs1799817) T TT 114 (61.3) 95 (60.9)	TT	142 (76.3)	106 (67.9)
CC92 (49.5) $77 (49.4)$ AA18 (9.7)8 (5.1)CA76 (40.9)71 (45.5)Insulin $T1 = 10000000000000000000000000000000000$	TG	42 (22.6)	46 (29.5)
AA 18 (9.7) 8 (5.1) CA 76 (40.9) 71 (45.5) Insulin Pm1l T > C (rs1799817) TT 114 (61.3) 95 (60.9)	Bsmal C > A (rs1501299)		
CA 76 (40.9) 71 (45.5) Insulin Pm1I T > C (rs1799817) TT 114 (61.3) 95 (60.9)	СС	92 (49.5)	77 (49.4)
Insulin Pm1l T > C (rs1799817) TT 114 (61.3) 95 (60.9)	АА	18 (9.7)	8 (5.1)
Pm1l T > C (rs1799817) TT 114 (61.3) 95 (60.9)	СА	76 (40.9)	71 (45.5)
TT 114 (61.3) 95 (60.9)	Insulin		
	Pm1l T > C (rs1799817)		
CC 15 (8.1) 7 (4.5)	тт	114 (61.3)	95 (60.9)
	СС	15 (8.1)	7 (4.5)
TC 57 (30.6) 54 (34.6)	TC	57 (30.6)	54 (34.6)

Table III: Genotype, allele, and haplotype frequencies in the two groups of study.

	PCOS (n = 186)	Controls (n = 156)
Nsil A > G (rs2059806)		
АА	11 (5.9)	18 (11.5)
GG	99 (53.2)	80 (51.3)
AG	76 (40.9)	58 (37.2)
Allele frequency (%)		
Smal T > G		
G	46	54
Т	326	258
Bsmal C > A		
С	260	225
А	112	87
Pm1l T > C		
т	285	244
С	87	68
Nsil A > G		
А	98	94
G	274	218

Fahimeh Ramezani Tehrani¹ M.D., Maryam Daneshpour² Ph.D., Somayeh Hashemi¹ M.Sc., Maryam Zarkesh² M.Sc., Feridoun Azizi³ M.D.

¹Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

²Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

³Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

*Corresponding author: Fahimeh Ramezani Tehrani;

Shahid Beheshti University of Medical Sciences, 24 Parvaneh, Yaman Street, Velenjak, Tehran, Iran. Postal Code: 19395-4763.

email: ramezani@endocrine.ac.ir

Tel: (+98) 2122409309

References

- [1] Ramezani Tehrani F, Daneshpour M, Hashemi S, Zarkesh M, Azizi F. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. *Iran J Reprod Med* 2013; 11: 185–194.
- [2] Munnangi S, Boktor SW. Epidemiology of study design. StatPearls 2018.
- [3] Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev* 2012; 33: 981–1030.

Editorial

Thanks to Dr. Chun Feng and Colleagues for their comments on the article that was published in our journal issued 2013; 11: 185-194. The modified version of this article will be uploaded in our electronic version (March 2019).